• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abiomed, FDA come to terms on Impella PMA requirements

Abiomed, FDA come to terms on Impella PMA requirements

March 22, 2016 By Brad Perriello

AbiomedAbiomed (NSDQ:ABMD) said yesterday that it came to terms with the FDA over the indications for use for its Impella line of cardiac assist devices and doesn’t believe it will have to appear before 1 of the agency’s advisory panels.

Danvers, Mass.-based Abiomed said the federal safety watchdog agreed on the indication for treating patients in cardiogenic shock after a heart attack or cardiac surgery with its Impella 2.5, Impella CP, Impella 5.0 and Impella LD devices.

“Based on the information available to the company to date, including multiple discussions with the FDA, the company no longer anticipates the requirement for an FDA advisory panel prior to the PMA approval,” the company said in a regulatory filing.

Abiomed said it submitted data from its 415-patient Recover 1 study, a review of data from another 692 patients in 17 trials, and a safety analysis of more than 24,000 patients using the FDA’s medical device reporting database.

“The company believes this is the most comprehensive review ever submitted to the FDA for circulatory support in the cardiogenic shock population,” the company said.

Leerink Partners analyst Danielle Antalffy said Abiomed’s timeline for approval is now “well ahead of the previously expected August 2016 timeframe.” Although cardiogenic shock already represents more than 40% of Impella sales, Abiomed hasn’t had an aggressive marketing push under its 510(k) clearance and has only a roughly 5% penetration into the 100,000-patient market, Antalffy wrote this morning in a note to investors.

“With a PMA approval for its suite of products in cardiogenic shock, ABMD will now be able to aggressively market to and train physicians and nurses using its extensive supportive clinical dataset – the most comprehensive ever in this indication,” she wrote.

“Upon approval, Impella will be the only temporary circulatory support device – vs. intra-aortic balloon pumps and [extracorporeal membrane oxygenation] – with ‘safe and effective’ on the label, something we believe will drive accelerating adoption and utilization. This is on top of the ~121,000-patient protected [percutaneous coronary intervention] market opportunity already being addressed by Impella 2.5 and also just ~5% penetrated,” Antalffy wrote.

Filed Under: Cardiovascular, Food & Drug Administration (FDA), Regulatory/Compliance, Structural Heart Tagged With: Abiomed

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy